The U.S. IPO market is set for a quiet start to the fourth quarter, with no offerings currently scheduled for the week ahead. While several companies are eligible to launch, including neocloud provider Nscale, autoimmune biotech TRex Bio and cancer biotech Iambic Therapeutics appear to be among the more likely candidates, while attention increasingly centers on artificial intelligence giant Anthropic and its reported plans to begin marketing an IPO as early as the week of November 9.
IPO Market Outlook
The absence of scheduled IPOs highlights a relatively subdued opening for the fourth quarter after a more active period for new listings. Several companies remain eligible to launch, meaning the calendar could change quickly if issuers and underwriters move forward with deals.
Nscale, a neocloud company, is among the companies positioned to potentially enter the market under the ticker NSCL. However, the most likely candidates identified for the coming week are TRex Bio, an autoimmune biotechnology company expected to trade under TRXB, and Iambic Therapeutics, a cancer-focused biotechnology company expected to trade under IAM.
The biotechnology pipeline could therefore provide the market with its next source of new issuance even as broader IPO activity remains limited.
Anthropic IPO Emerges as Major Market Catalyst
Beyond the companies already in the public pipeline, Anthropic is becoming an increasingly important factor for the fourth-quarter IPO market.
The artificial intelligence company is reportedly firming up its listing timeline, with marketing potentially beginning as soon as the week of November 9. If that timetable materializes, Anthropic could become one of the most closely watched technology IPOs in years, with its reception likely to influence investor sentiment toward other large private technology companies considering public listings.
The prospect of an Anthropic offering also gives the fourth-quarter IPO calendar a potential marquee transaction after a relatively quiet start.
IPO Market Snapshot
As of October 1, 2026, the Renaissance IPO Index was up 16.4% year to date, compared with a 13.0% gain for the S&P 500. The Renaissance IPO Index is a market-cap-weighted basket of newly public companies, while the Renaissance Capital IPO ETF tracks the index.
Among the ETF’s leading holdings are Astera Labs and SK hynix, highlighting the continued influence of semiconductor and technology companies within the recent IPO market.
International IPO performance has been even stronger. The Renaissance International IPO Index was up 28.5% year to date, compared with a 13.8% gain for the ACWX ex-US benchmark. The International IPO ETF includes companies such as Kioxia and Galderma among its leading holdings.
Lock-Up Expirations
Four IPO lock-up periods are scheduled to expire during the week ahead. These expirations can increase the amount of stock potentially available for trading by existing shareholders and may become relevant for investors monitoring recently listed companies.
The supplied source does not identify the four companies associated with the upcoming expirations.
Market Context and Opportunities
The contrast between a quiet primary issuance calendar and relatively strong year-to-date IPO index performance suggests that investor appetite for newly public companies has not disappeared. Instead, performance remains concentrated among selected companies and sectors.
The biotechnology candidates in the immediate pipeline could provide another test of demand for growth-oriented businesses, while Anthropic represents a much larger potential event for the technology market.
The continued strength of both the U.S. and international IPO indices also indicates that companies able to demonstrate compelling growth prospects and credible market positioning may still find receptive investors despite periods of reduced issuance.
Risks and Challenges
The biggest uncertainty for the week ahead is the limited number of confirmed launches. Companies that are eligible to launch are not necessarily guaranteed to proceed, leaving the actual calendar dependent on market conditions and issuer decisions.
Anthropic’s potential timeline is also based on reported plans rather than a confirmed IPO launch date in the supplied source. As a result, investors should distinguish between a developing pipeline and transactions that have formally entered the public offering process.
More broadly, the performance of newly public companies remains uneven, meaning strong index-level returns do not necessarily translate into broad-based gains across every recent IPO.
Closing Paragraph
The fourth quarter is beginning with little scheduled IPO activity, but the market’s quiet opening could prove temporary. TRex Bio and Iambic Therapeutics offer potential near-term biotech issuance, while Nscale remains eligible to launch, but the larger story is Anthropic, whose reported November marketing timeline could transform the final-quarter IPO landscape. With the Renaissance IPO Index already outperforming the S&P 500 year to date, investors will be watching closely to see whether the next wave of major listings can sustain that momentum
